Renal Osteodystrophy Explained: High-Turnover Bone Disease, Adynamic Bone Disease, Osteomalacia and Bone Biopsy

What Is Renal Osteodystrophy?

Core Teaching Question

In a patient with chronic kidney disease, what is actually happening inside the bone—excessive turnover, suppressed turnover, defective mineralization, or a mixture of abnormalities—and how can PTH, alkaline phosphatase, DXA and bone biopsy help distinguish these patterns?

Central Concept

but:

Then:

is classified by:

This distinction is fundamental.

KDIGO defines CKD-MBD as a systemic disorder that can involve biochemical abnormalities, bone abnormalities and vascular/soft-tissue calcification, whereas renal osteodystrophy specifically refers to altered bone morphology in CKD and is quantifiable by bone histomorphometry. (KDIGO)

Renal osteodystrophy (ROD) is the term used for the characteristic abnormalities of bone morphology that occur as part of chronic kidney disease–mineral and bone disorder.

It is important not to use the terms:

and:

as though they mean exactly the same thing.

CKD-MBD is the broader systemic disorder.

It can include:

• abnormalities of calcium;
• abnormalities of phosphate;
• abnormalities of PTH;
• abnormalities of vitamin D metabolism;
• abnormal bone turnover;
• abnormal bone mineralization;
• abnormal bone volume or strength;
• vascular calcification;
• soft-tissue calcification.

Renal osteodystrophy is specifically:

The most accurate way to classify renal osteodystrophy is by bone histomorphometry.

The modern framework asks three major questions:

These correspond to:

or:

This framework is more useful than simply labeling all CKD-related skeletal disease as “renal bone disease.”

Why CKD Affects Bone

Bone disease in CKD develops from interacting disturbances rather than from one abnormal laboratory value.

Important contributors include:

• phosphate retention;
• altered FGF23 physiology;
• reduced renal calcitriol production;
• abnormalities of calcium balance;
• secondary hyperparathyroidism;
• metabolic acidosis in some patients;
• uremic effects on bone cells;
• changes in sex hormones;
• diabetes;
• inflammation;
• nutrition;
• medications;
• dialysis-related factors.

Therefore:

and:

CKD-MBD Versus Renal Osteodystrophy

Bottom:

KDIGO reserves renal osteodystrophy for the skeletal histological component of CKD-MBD. (KDIGO)

Why The Term Matters Clinically

Consider two CKD patients with elevated PTH.

They may not have the same bone disease.

One may have:

while another may have:

Therefore:

Similarly, two patients with low bone density on DXA may have completely different underlying bone remodeling patterns.

This is why renal osteodystrophy classification matters.

The TMV Classification

Tmv Classification

How rapidly is bone being formed and resorbed?

Possible states:

• high;
• normal;
• low.

Is newly formed osteoid being mineralized normally?

Possible states:

• normal;
• abnormal.

How much bone is present?

Possible states:

• high;
• normal;
• low.

The TMV system was developed to describe the histological abnormalities of renal osteodystrophy more systematically. Bone biopsy can directly assess these domains. (PubMed Central (PMC))

Why Turnover Is Important

Bone is continuously remodeled.

A remodeling cycle involves:

followed by:

If this process is excessively active:

If very few remodeling units are active:

Both extremes can produce clinically important bone disease.

Therefore:

and:

Why Mineralization Is A Separate Concept

Bone formation has two important stages.

First:

Then:

A patient may produce relatively normal amounts of osteoid but fail to mineralize it properly.

This is fundamentally different from having almost no bone formation.

Therefore:

and:

The defining problem in osteomalacia is:

Why Bone Volume Is Separate

Bone volume reflects the amount of bone present.

Turnover does not automatically determine bone volume.

For example:

• high turnover can coexist with low, normal or sometimes relatively preserved bone volume;
• low turnover can coexist with reduced or near-normal volume.

Therefore:

and:

Types of Renal Osteodystrophy

Major Types Of Renal Osteodystrophy

High-turnover patterns

Hyperparathyroid bone disease / osteitis fibrosa

Turnover: high

Mineralization: usually normal

Mixed uremic osteodystrophy

Turnover: often high

Mineralization: abnormal

Low-turnover patterns

Adynamic bone disease

Turnover: low

Mineralization: usually normal

Osteomalacia

Turnover: usually low

Mineralization: abnormal

Modern ROD reviews consistently use these turnover/mineralization combinations. (PubMed Central (PMC))

Master Comparison Table

Directly below:

These are characteristic patterns rather than rigid biochemical definitions. (PubMed Central (PMC))

High-Turnover Bone Disease

High-Turnover Bone Disease

High-turnover renal bone disease develops when bone remodeling is excessively stimulated.

The major classical driver is:

Pathway:

This is why severe hyperparathyroidism produces a high-turnover lesion rather than simply causing bone resorption alone.

Osteitis Fibrosa

The classical severe high-turnover lesion is:

Features include increased:

• osteoclastic resorption;
• osteoblastic activity;
• remodeling surfaces;
• woven bone in severe disease;
• marrow/peritrabecular fibrosis.

Advanced hyperparathyroid bone disease can also be associated with:

• skeletal pain;
• fragility;
• deformity;
• fractures;
• brown tumors in extreme cases.

Recent biopsy-based work continues to classify osteitis fibrosa as high-turnover disease with generally preserved mineralization. (PubMed Central (PMC))

Secondary Hyperparathyroidism

Osteitis Fibrosa Does Not Mean Osteoporosis

Osteitis fibrosa describes a high-turnover histological process related to hyperparathyroidism.

Osteoporosis describes reduced bone strength and fracture susceptibility.

A patient may have both, but they are not synonyms.

PTH In High-Turnover Disease

Markedly elevated PTH increases the probability of high-turnover disease.

However:

There is substantial overlap among patients.

Therefore:

but not:

KDIGO recommends using PTH and bone-specific alkaline phosphatase because markedly high or low values can help predict underlying turnover. (KDIGO)

ALP In High-Turnover Disease

High bone turnover increases osteoblastic activity.

Therefore:

Total alkaline phosphatase may also be elevated.

However:

Therefore an isolated high total ALP should not automatically be attributed to bone.

Bone-Specific Alkaline Phosphatase

Bone-specific alkaline phosphatase is produced by osteoblasts.

It therefore reflects:

In CKD:

• markedly high bone-specific ALP supports higher turnover;
• markedly low values can support suppressed turnover.

It is particularly useful because it is less dependent on renal clearance than some other bone-turnover markers.

Still:

Adynamic Bone Disease ### Core concept

Adynamic bone disease (ABD) is the major low-turnover phenotype of renal osteodystrophy.

Its defining physiological problem is:

There are relatively few active remodeling units, with markedly reduced bone formation and reduced remodeling activity.

Typical histological features include:

• reduced osteoblast activity;
• very low bone-formation rate;
• relatively few active osteoclasts;
• reduced remodeling surfaces;
• sparse or absent dynamic tetracycline labeling.

The crucial distinction is:

while:

This separates ABD from osteomalacia.

Memory statement

Formation ↓ | Resorption ↓ | Turnover ↓↓

Why adynamic bone disease is not simply “low PTH”

A low or relatively suppressed PTH level is an important clue to low bone turnover.

However:

and:

Bone turnover depends not only on the circulating concentration of PTH but also on how effectively the skeleton responds to PTH.

Modern evidence therefore describes two broad routes to low-turnover bone disease:

and/or:

A recent meta-analysis and narrative review identifies both excessive suppression of PTH and multiple causes of skeletal PTH hyporesponsiveness as important mechanisms of ABD. (PubMed Central (PMC))

Pathway 1 — excessive suppression of PTH drive

Potential contributors include:

• high calcium exposure;
• calcium-containing phosphate binders in appropriate contexts;
• active vitamin-D therapy;
• calcimimetic therapy;
• dialysis-related calcium exposure;
• previous parathyroidectomy.

The conceptual pathway is:

The potential problem is:

Pathway 2 — skeletal hyporesponsiveness to PTH

Low turnover can also develop because bone does not respond normally to available PTH.

Potential contributors include:

• diabetes mellitus;
• advanced age;
• malnutrition;
• chronic inflammation;
• uremic factors;
• altered osteoblast biology.

This explains why:

yet:

The recent review specifically discusses diabetes, malnutrition, inflammation and uremic toxins such as indoxyl sulfate as contributors to PTH hyporesponsiveness and low-turnover physiology. (PubMed Central (PMC))

Diabetes and adynamic bone

Diabetes is an important clinical association with low-turnover renal bone disease.

Potential mechanisms include alterations in:

• osteoblast function;
• insulin and IGF signaling;
• advanced glycation;
• inflammatory signaling;
• skeletal responsiveness to PTH.

Therefore:

should raise suspicion of ABD.

However:

Aging, malnutrition and inflammation

Older patients with CKD frequently have additional factors that suppress bone formation.

Malnutrition and chronic inflammation may impair:

• osteoblast function;
• anabolic signaling;
• skeletal response to PTH.

Therefore medication review alone is not sufficient.

ABD is usually:

Uremic factors

Accumulating uremic toxins may contribute to impaired osteoblast biology and skeletal PTH resistance.

Indoxyl sulfate is one example that has been investigated in this context.

PTH and bone-specific alkaline phosphatase

The most clinically useful non-invasive clues are:

and:

KDIGO recommends these markers because markedly high or markedly low values can predict underlying bone turnover. (KDIGO)

Markedly low PTH

Makes:

Markedly low BSAP

Supports:

Low PTH + low BSAP

Together increase suspicion for:

But:

PTH must be interpreted within the patient's:

• CKD stage;
• calcium;
• phosphate;
• treatment exposure;
• previous PTH level;
• longitudinal trend.

A value that lies within a general laboratory reference range does not necessarily prove that skeletal remodeling is adequate in advanced CKD.

Therefore:

and:

Adynamic bone and skeletal mineral buffering

Bone is not merely structural tissue.

It also functions as a dynamic reservoir for calcium and phosphate.

When remodeling becomes extremely low:

As a result, the skeleton may have less capacity to accommodate calcium loads dynamically.

This helps explain why calcium exposure deserves particular attention when low-turnover bone disease is suspected.

ABD and low-turnover states have been associated with:

• hypercalcemic tendencies in some settings;
• vascular calcification;
• fracture;
• adverse clinical outcomes.

However:

CKD vascular calcification is multifactorial, involving phosphate, calcium, vascular-cell biology, inflammation, renal failure and other CKD-MBD processes.

Recent literature continues to describe reduced calcium-buffering capacity and associations between low-turnover disease and arterial calcification, while emphasizing the complexity of causal interpretation. (PubMed Central (PMC))

Osteomalacia and Mixed Uremic Osteodystrophy

Osteomalacia

Osteomalacia is fundamentally:

Therefore bone tissue contains excessive unmineralized osteoid.

In the TMV framework:

Turnover is commonly low.

Potential causes relevant to CKD may include:

• severe vitamin D deficiency or disturbed vitamin D metabolism;
• severe phosphate depletion;
• aluminum toxicity in appropriate exposure settings;
• other metabolic or medication-related causes.

Osteomalacia

Osteomalacia Versus Adynamic Bone Disease

Vitamin D Deficiency

Vitamin D deficiency can contribute to defective mineralization.

However:

Many patients with vitamin D deficiency do not have histological osteomalacia.

Osteomalacia describes the bone lesion.

Vitamin D deficiency is one potential cause.

Vitamin D Deficiency

Vitamin D Metabolism

Phosphate Depletion And Osteomalacia

Adequate phosphate is required to mineralize bone.

Chronic severe phosphate deficiency can therefore produce:

This mechanism is particularly relevant to the broader phosphate cluster.

Hypophosphatemia

Renal Phosphate Wasting

FGF23 Disorders

Aluminum-Related Osteomalacia

Historically, aluminum exposure was a major cause of low-turnover/mineralization bone disease in dialysis populations.

With changes in dialysis water purification and medication practices, classical aluminum toxicity is less common in many modern settings.

However it remains clinically relevant where exposure is possible.

Mixed Uremic Osteodystrophy

Some patients have both:

and:

This is commonly termed:

The key teaching point is:

A patient can have strong hyperparathyroid remodeling while simultaneously failing to mineralize newly formed osteoid normally.

Recent biopsy classification continues to recognize mixed disease as high/variable turnover with abnormal mineralization. (PubMed Central (PMC))

Why “Four Boxes” Are Still An Oversimplification

Real bone biology exists on a continuum.

Patients can transition over time:

therapy / changing CKD physiology

excessive suppression or other factors

Similarly, mineralization abnormalities can appear or resolve independently.

Therefore:

and:

Laboratory Evaluation

Laboratory Evaluation

Important biochemical assessment can include:

Additional testing depends on the clinical context.

No laboratory combination is perfectly diagnostic of the ROD subtype.

Why Calcium Alone Tells Little About Turnover

Serum calcium is tightly regulated.

A patient may have significant bone disease while serum calcium remains:

Therefore:

This is particularly important in CKD.

Why Phosphate Alone Tells Little About Bone Histology

Hyperphosphatemia is common in advanced CKD and contributes to CKD-MBD.

But:

Similarly:

Phosphate is part of the biochemical context rather than a histological classification test.

PTH As A Turnover Marker

but:

Markedly high values suggest high turnover.

Markedly low values suggest low turnover.

Intermediate values have substantial overlap.

Therefore:

KDIGO specifically states that serum PTH or bone-specific alkaline phosphatase can be used to evaluate bone disease because markedly high or low values predict underlying turnover. (KDIGO)

One PTH Value Is Not Enough

CKD-MBD treatment decisions should not be based on one isolated laboratory result.

Interpret:

rather than:

A rising PTH over time may convey different information from a stable PTH at the same concentration.

Secondary Hyperparathyroidism

Bone Turnover Markers In CKD

Some common bone-turnover markers are affected by renal clearance.

Therefore their concentrations may rise simply because kidney function declines.

This complicates interpretation.

KDIGO has not recommended routine use of collagen synthesis/breakdown markers such as:

• procollagen type I C-terminal propeptide;
• collagen type I cross-linked telopeptide;
• pyridinoline;
• deoxypyridinoline;

for routine turnover assessment in CKD G3a–G5D. (KDIGO)

DXA, Osteoporosis and Renal Osteodystrophy

DXA In CKD

Dual-energy X-ray absorptiometry measures:

It can help estimate fracture risk.

Current KDIGO guidance supports BMD testing in CKD G3a–G5D when the result would influence treatment decisions in patients with CKD-MBD and/or osteoporosis risk factors. (KDIGO)

Therefore the outdated statement:

is incorrect.

What DXA Cannot Tell You

DXA cannot tell you:

• turnover rate;
• whether mineralization is normal;
• whether bone is adynamic;
• whether osteomalacia is present;
• whether mixed uremic osteodystrophy exists.

Therefore:

but not:

Non-invasive imaging can assess bone mass and aspects of structure, but it does not directly define turnover and mineralization as histomorphometry does. (PubMed Central (PMC))

Renal Osteodystrophy Versus Osteoporosis

describes:

and is commonly evaluated using:

• DXA;
• fracture history;
• clinical risk factors.

describes:

Therefore a patient can have:

• osteoporosis without ROD;
• ROD without osteoporosis;
• both simultaneously.

Why The Distinction Matters Before Osteoporosis Treatment

A patient with CKD and low BMD may also have:

or:

or:

These conditions may influence treatment strategy.

Therefore:

KDIGO recommends considering the magnitude/reversibility of CKD-MBD abnormalities and disease progression when treating low BMD/fracture in CKD G3a–G5D. Bone biopsy may be considered when knowledge of the ROD subtype would change management. (KDIGO)

Bone Biopsy and Histomorphometry

Bone Biopsy

Bone biopsy with histomorphometry remains the:

for characterizing renal osteodystrophy.

It can directly evaluate:

as well as cellular and structural features.

Double tetracycline labeling allows dynamic analysis of formation and mineralization. (PubMed Central (PMC))

Where Is Bone Biopsy Performed?

The classical biopsy site is:

A transiliac sample allows assessment of both cortical and trabecular bone. For the purpose of understanding renal osteodystrophy, the important point is what the biopsy measures rather than the procedural technique used to obtain it.

Static Histomorphometry

Static histomorphometry examines structural features present in the biopsy.

It can assess:

• bone volume;
• osteoid amount;
• osteoblast surfaces;
• osteoclast surfaces;
• fibrosis;
• architecture.

This tells us what the bone looks like at the time of biopsy.

Dynamic Histomorphometry

Dynamic histomorphometry examines:

This is made possible by fluorescent labels deposited during bone mineralization.

It helps estimate:

• mineral apposition;
• bone formation;
• mineralization timing.

This is one of the reasons histomorphometry can identify abnormalities that serum tests cannot. (PubMed Central (PMC))

Tetracycline Labeling

Tetracycline binds to sites where mineral is being deposited.

Under fluorescence microscopy it produces visible labeling lines.

If two labels are administered at different times:

can provide information about:

and:

What Tetracycline Patterns Can Teach

Active bone formation

Distinct fluorescent labels can be seen at actively mineralizing surfaces.

Very low turnover

There may be very little labeling because few sites are actively forming bone.

Mineralization defect

Abnormal relationships between osteoid and mineralization labels can reveal delayed mineralization.

Therefore:

Is Bone Biopsy Required For Everyone With CKD?

Bone biopsy is invasive and requires specialist expertise.

KDIGO recommends that it is reasonable to perform bone biopsy when knowing the type of renal osteodystrophy would affect treatment decisions. (KDIGO)

Therefore:

When Might Bone Biopsy Be Useful?

Potential contexts include:

• unexplained fractures;
• major discrepancy between clinical findings and biomarkers;
• suspected mineralization defect;
• suspected aluminum-related bone disease;
• unexplained hypercalcemia or hypophosphatemia in selected CKD contexts;
• difficult therapeutic decisions where high versus low turnover would materially change management;
• selected patients being considered for osteoporosis therapy when CKD-MBD abnormalities create major diagnostic uncertainty.

The exact indication must be individualized.

Specialty guidance and reviews emphasize biopsy when the result is expected to change treatment rather than as routine screening. (PubMed Central (PMC))

Bone Biopsy Limitations

Important limitations include:

• invasiveness;
• availability;
• need for expertise;
• specialized histomorphometry laboratories;
• patient discomfort;
• cost;
• delays in processing/reporting;
• sampling one skeletal site rather than the entire skeleton.

Therefore:

Diagnostic Pathway

YES

PTH-drive suppression

• calcium exposure;
• active vitamin-D treatment;
• calcimimetic treatment;
• dialysis calcium exposure;
• previous parathyroidectomy.

PTH hyporesponsiveness / systemic factors

• diabetes;
• aging;
• malnutrition;
• inflammation;
• uremic factors.

YES

Consider:

→ DXA when result will change management.

YES

Treatment According to Bone Phenotype

High-Turnover Treatment Concept

High-turnover renal bone disease is most often driven by excessive PTH signaling.

Management therefore focuses on correcting the CKD-MBD factors driving secondary hyperparathyroidism.

Depending on CKD stage and clinical context, management may involve:

• phosphate control;
• correction of important calcium abnormalities;
• correction of vitamin D deficiency where appropriate;
• active vitamin-D strategies in selected patients;
• calcimimetics in appropriate advanced CKD settings;
• dialysis-related management;
• parathyroidectomy for severe refractory hyperparathyroidism.

The treatment goal is:

not:

Secondary Hyperparathyroidism

Parathyroidectomy

Adynamic-Bone Treatment Concept

Adynamic bone disease represents a fundamentally different therapeutic problem from severe high-turnover secondary hyperparathyroidism.

The patient already has:

Therefore the treatment principle is:

But the therapeutic goal is not:

or:

Instead:

Review calcium exposure

Consider the total calcium burden from:

• diet;
• supplements;
• calcium-containing phosphate binders;
• dialysis exposure where relevant.

If the calcium burden is unnecessarily high, reducing avoidable exposure may help prevent continued PTH/turnover suppression.

Review active vitamin-D therapy

Active vitamin-D compounds have important therapeutic roles in selected patients.

However, if:

and:

the continuing intensity and indication for PTH-suppressive treatment should be reassessed.

Excessive suppression of PTH in susceptible patients can contribute to low-turnover physiology.

Review calcimimetic treatment

Calcimimetics are useful therapies for appropriate secondary-HPT patients.

But treatment success does not mean:

If PTH becomes persistently and substantially suppressed and low-turnover disease is suspected, the overall CKD-MBD regimen should be reviewed.

Review dialysis calcium where relevant

Dialysate calcium contributes to the patient's total calcium balance and influences PTH secretion.

Therefore it belongs in the review of suspected low-turnover disease.

Address non-treatment contributors

Also assess:

• diabetes;
• malnutrition;
• chronic inflammation;
• reduced mobility;
• glucocorticoid exposure;
• hypogonadism;
• other major skeletal risk factors.

This prevents the incorrect assumption that every case of ABD is iatrogenic.

What About Antiresorptive Osteoporosis Therapy?

Antiresorptive drugs reduce bone remodeling.

This creates an understandable concern when the patient may already have:

However, the evidence does not support teaching that every antiresorptive drug is absolutely contraindicated in every CKD patient with suspected ABD.

The correct principle is:

Treatment decisions should consider:

• CKD stage;
• fracture history;
• BMD;
• CKD-MBD abnormalities;
• likelihood of low turnover;
• drug-specific risks;
• whether bone biopsy would materially change management.

Recent review evidence highlights continuing uncertainty regarding antiresorptive therapy in advanced CKD patients with low-turnover disease. (PubMed Central (PMC))

Are Anabolic Therapies the Solution?

Because ABD is characterized by reduced bone formation, osteoanabolic therapy is biologically attractive.

PTH analogues and sclerostin-directed therapy have been studied or proposed in selected low-turnover CKD populations.

However:

Use this as an advanced-evidence note only.

Recent review literature describes anabolic approaches as promising but still requiring individualized application and stronger outcome evidence in advanced CKD. (PubMed Central (PMC))

Osteomalacia Treatment Concept

Treatment must address the reason mineralization is failing.

Depending on cause, this can include correction of:

• vitamin D deficiency;
• phosphate deficiency;
• abnormal phosphate handling;
• relevant toxic exposures;
• other metabolic causes.

Osteomalacia

Vitamin D Deficiency

Hypophosphatemia

Mixed-Disease Treatment Concept

Mixed uremic osteodystrophy presents a more complicated problem because:

Therefore simply suppressing PTH aggressively may not address the entire bone lesion.

Management requires identification of:

• the high-turnover driver;
• the mineralization defect;
• the broader CKD-MBD context.

This is a good example of why histological classification can matter.

Fracture Risk and Vascular Calcification

Fracture Risk

Patients with CKD have increased fracture risk.

Multiple contributors include:

• abnormal turnover;
• altered mineralization;
• reduced bone mass;
• cortical abnormalities;
• falls;
• age;
• diabetes;
• frailty;
• medications.

Therefore:

and:

Vascular Calcification

CKD-MBD also involves vascular and soft-tissue calcification.

This is related to disturbances in:

• phosphate;
• calcium;
• cellular calcification pathways;
• renal failure;
• bone-mineral buffering.

But vascular calcification should not be classified as:

It belongs to the broader:

framework.

Hungry Bone, Tertiary HPT and Transplant Bone Disease

Relationship To Hungry Bone Syndrome

High-turnover renal osteodystrophy becomes clinically important around parathyroid surgery.

Before surgery:

After successful parathyroidectomy:

Therefore preoperative high-turnover bone disease helps explain why HBS can be so profound after renal parathyroidectomy.

Acute postoperative hungry bone syndrome is distinct from ABD.

Relationship To Tertiary Hyperparathyroidism

Long-standing severe secondary HPT can progress to:

These patients may have substantial high-turnover bone disease before transplantation or parathyroid surgery.

Tertiary Hyperparathyroidism

Post-Transplant Bone Disease

Kidney transplantation corrects many abnormalities of advanced kidney failure.

But:

Post-transplant bone disease may reflect:

• pre-existing renal osteodystrophy;
• persistent hyperparathyroidism;
• tertiary hyperparathyroidism;
• glucocorticoid exposure;
• osteoporosis;
• age;
• diabetes;
• altered post-transplant mineral physiology.

Therefore:

and should not automatically be labeled tertiary HPT or osteoporosis.

Can Renal Osteodystrophy Improve?

Yes.

Bone turnover and mineralization can change as:

• kidney function changes;
• transplantation occurs;
• secondary HPT is treated;
• phosphate control changes;
• vitamin D therapy changes;
• parathyroidectomy is performed.

Therefore ROD is not necessarily a permanent fixed phenotype.

Worked Clinical Cases

Common Mistakes

Mistake 1

CKD-MBD and renal osteodystrophy mean the same thing.

Wrong.

Mistake 2

Every CKD patient with high PTH has osteitis fibrosa.

Wrong.

Mistake 3

PTH directly measures bone turnover.

Wrong.

Mistake 4

A normal-range PTH excludes adynamic bone disease.

Wrong.

Mistake 5

High PTH is always harmful and should be normalized completely.

Wrong.

Mistake 6

Low PTH is always desirable.

Wrong.

Mistake 7

Adynamic bone disease means osteomalacia.

Wrong.

Mistake 8

Osteomalacia is simply low bone turnover.

Wrong.

Mistake 9

Every patient with suspected ABD should stop active vitamin D or calcimimetic therapy.

Wrong.

Mistake 10

Total ALP always reflects bone.

Wrong.

Mistake 11

DXA identifies the ROD subtype.

Wrong.

Mistake 12

A low T-score means the patient has adynamic bone.

Wrong.

Mistake 13

Osteoporosis and renal osteodystrophy are mutually exclusive.

Wrong.

Mistake 14

All antiresorptive drugs are absolutely contraindicated whenever ABD is suspected.

Wrong.

Mistake 15

Bone biopsy is required for every CKD patient.

Wrong.

Mistake 16

Bone biopsy has no role because serum PTH gives the same information.

Wrong.

Mistake 17

High-turnover ROD involves only osteoclastic resorption.

Wrong. Both resorption and formation are increased.

Mistake 18

Adynamic bone is caused only by treatment.

Wrong.

Mistake 19

The treatment of ABD is simply to raise PTH.

Wrong.

Mistake 20

All post-transplant bone disease is tertiary hyperparathyroidism.

Wrong.

Renal Osteodystrophy in One Minute

One-Minute Revision

RENAL OSTEODYSTROPHY IN ONE MINUTE

is the systemic disorder.

is the bone histology.

Classify using:

TURNOVER HIGH + MINERALIZATION NORMAL

TURNOVER LOW + MINERALIZATION NORMAL

TURNOVER LOW + MINERALIZATION ABNORMAL

TURNOVER HIGH + MINERALIZATION ABNORMAL

but:

Golden Memory Table

Bottom:

Frequently Asked Questions

Key Take-Home Messages

Renal osteodystrophy is best understood by asking:

Chronic kidney disease alters:

• phosphate physiology;
• vitamin D metabolism;
• calcium balance;
• PTH secretion;
• bone-cell activity.

But these disturbances do not produce one identical bone lesion in every patient.

Some patients develop:

This produces high-turnover hyperparathyroid bone disease and, in severe cases:

Other patients develop:

This produces:

Others develop:

This produces:

And some patients have both high turnover and defective mineralization:

The most useful conceptual framework is therefore:

PTH and bone-specific alkaline phosphatase can help estimate turnover, particularly at marked extremes.

But:

DXA can help assess bone mineral density and fracture risk.

But:

When the exact type of bone disease would materially change treatment:

remains the reference method.

Therefore the diagnostic sequence should be:

The final memory statement should be: